Insights into the preclinical treatment of blood-stage malaria by the antibiotic borrelidin

British Journal of Pharmacology

Volumn 169, Issue 3, 2013, Pages 645-658

  Azcarate I G ^a   Marin Garcia P ^a,d   Camacho, N ^b   Perez Benavente S ^a   Puyet, A ^a   Diez, A ^a   Ribas De Pouplana, L ^b,c   Bautista, J M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^d UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

aminoacyl tRNA synthetases; borrelidin; humoral response; malaria; Plasmodium; treatment

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; BORRELIDIN; CHLOROQUINE; IMMUNOGLOBULIN G; PARASITE ANTIGEN; PSEUDOMONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMALARIAL ACTIVITY; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG TARGETING; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL MEMORY; LOW DRUG DOSE; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM YOELII INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; REINFECTION; SCHIZONT; SURVIVAL; TROPHOZOITE;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY AFFINITY; ANTIMALARIALS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FATTY ALCOHOLS; FEMALE; IMMUNITY, HUMORAL; MALARIA; MICE; MICE, INBRED STRAINS; MUPIROCIN; PARASITEMIA; PLASMODIUM YOELII; PROTOZOAN PROTEINS; RANDOM ALLOCATION; RECURRENCE; SCHIZONTS; SPECIFIC PATHOGEN-FREE ORGANISMS; SURVIVAL ANALYSIS; THREONINE-TRNA LIGASE;

EID: 84877803986     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12156     Document Type: Article

References (69)

1. Achtman AH, Bull PC, Stephens R, Langhorne J, (2005). Longevity of the immune response and memory to blood-stage malaria infection. In:, Langhorne J, (ed.). Immunology and Immunopathogenesis of Malaria, 1st edn. Springer: Berlin-Heidelberg, pp. 71-102.
2. Achtman AH, Stephens R, Cadman ET, Harrison V, Langhorne J, (2007). Malaria-specific antibody responses and parasite persistence after infection of mice with Plasmodium chabaudi chabaudi. Parasite Immunol 29: 435-444.
3. Amante FH, Engwerda CR, Good MF, (2011). Experimental asexual blood stage malaria immunity. Curr Protoc Immunol 93: 19.14.01-19.14.26.
4. Bahamontes-Rosa N, Rodriguez-Alejandre A, Gonzalez-del-Rio R, Garcia-Bustos JF, Mendoza-Losana A, (2011). A new molecular approach for cidal vs static antimalarial determination by quantifying mRNA levels. Mol Biochem Parasitol 181: 171-177.
5. Barthel D, Schlitzer M, Pradel G, (2008). Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum. Antimicrob Agents Chemother 52: 774-777.
6. Beaudoin RL, Strome CP, Mitchell F, Tubergen TA, (1977). Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol 42: 1-5.
7. Berek C, (1993). Somatic mutation and memory. Curr Opin Immunol 5: 218-222.
8. Berger J, Jampolsky LM, Goldberg MW, (1949). Borrelidin, a new antibiotic with antiborrelia activity and penicillin enhancement properties. Arch Biochem 22: 476-478.
9. Bloland PB, (2001). Drug Resistance in Malaria. World Health Organization: Geneva.
10. Borrmann S, Matuschewski K, (2011). Protective immunity against malaria by 'natural immunization': a question of dose, parasite diversity, or both? Curr Opin Immunol 23: 500-508.
11. Boyle JS, Koniaras C, Lew AM, (1997). Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol 9: 1897-1906.
12. Bull PC, Lowe BS, Kaleli N, Njuga F, Kortok M, Ross A, et al. (2002). Plasmodium falciparum infections are associated with agglutinating antibodies to parasite-infected erythrocyte surface antigens among healthy Kenyan children. J Infect Dis 185: 1688-1691.
13. Cohen S, McGregor IA, Carrington S, (1961). Gamma-globulin and acquired immunity to human malaria. Nature 192: 733-737.
14. Collins WE, Jeffery GM, (1999). A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection. Am J Trop Med Hyg 61: 20-35.
15. Critchley IA, Young CL, Stone KC, Ochsner UA, Guiles J, Tarasow T, et al. (2005). Antibacterial activity of REP8839, a new antibiotic for topical use. Antimicrob Agents Chemother 49: 4247-4252.
16. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE, et al. (2010). A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A 107: 6958-6963.
17. Dickinson L, Griffiths AJ, Mason CG, Mills RF, (1965). Anti-viral activity of two antibiotics isolated from a species of Streptomyces. Nature 206: 265-268.
18. Doolan DL, Dobano C, Baird JK, (2009). Acquired immunity to malaria. Clin Microbiol Rev 22: 13-36.
19. Dorgerloh M, Kretschmer A, Schmidt RR, Steffens R, Zoebelein G, Tietjen K, et al. (1988). Borrelidin insecticide and herbicide, and its preparation by fermentation. German Patent 11, (1988) DE 3607287.
20. Druilhe P, Perignon JL, (1997). A hypothesis about the chronicity of malaria infection. Parasitol Today 13: 353-357.
21. Elliott SR, Kuns RD, Good MF, (2005). Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect Immun 73: 2478-2485.
22. Friesen J, Silvie O, Putrianti ED, Hafalla JC, Matuschewski K, Borrmann S, (2010). Natural immunization against malaria: causal prophylaxis with antibiotics. Sci Transl Med 2: 40ra49.
23. Funahashi Y, Wakabayashi T, Semba T, Sonoda J, Kitoh K, Yoshimatsu K, (1999). Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor. Oncol Res 11: 319-329.
24. Goldblatt D, Vaz AR, Miller E, (1998). Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 177: 1112-1115.
25. Goodman CD, Su V, McFadden GI, (2007). The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol Biochem Parasitol 152: 181-191.
26. Habibi D, Ogloff N, Jalili RB, Yost A, Weng AP, Ghahary A, et al. (2012). Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia. Invest New Drugs 30: 1361-1370.
27. Hoepfner D, McNamara CW, Lim CS, Studer C, Riedl R, Aust T, et al. (2012). Selective and specific inhibition of the Plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe 11: 654-663.
28. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, et al. (2002). Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155-1164.
29. Hughes J, Mellows G, (1978). Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid. Biochem J 176: 305-318.
30. Hurdle JG, O'Neill AJ, Chopra I, (2005). Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob Agents Chemother 49: 4821-4833.
31. Hutter R, Poralla K, Zachau HG, Zahner H, (1966). Metabolic products of microorganisms. 5l. On the mechanism of action of borrelidin-inhibition of the threonine incorporation in sRNA. Biochem Z 344: 190-196.
32. Ishiyama A, Iwatsuki M, Namatame M, Nishihara-Tsukashima A, Sunazuka T, Takahashi Y, et al. (2011). Borrelidin, a potent antimalarial: stage-specific inhibition profile of synchronized cultures of Plasmodium falciparum. J Antibiot 64: 381-384.
33. Istvan ES, Dharia NV, Bopp SE, Gluzman I, Winzeler EA, Goldberg DE, (2011). Validation of isoleucine utilization targets in Plasmodium falciparum. Proc Natl Acad Sci U S A 108: 1627-1632.
34. Jackson KE, Pham JS, Kwek M, De Silva NS, Allen SM, Goodman CD, et al. (2012). Dual targeting of aminoacyl-tRNA synthetases to the apicoplast and cytosol in Plasmodium falciparum. Int J Parasitol 42: 177-186.
35. Jayawardena AN, Targett GA, Leuchars E, Davies AJ, (1978). The immunological response of CBA mice to P. yoelii. II. The passive transfer of immunity with serum and cells. Immunology 34: 157-165.
36. Kamali AN, Marin-Garcia P, Azcarate IG, Diez A, Puyet A, Bautista JM, (2012). Plasmodium yoelii blood-stage antigens newly identified by immunoaffinity using purified IgG antibodies from malaria-resistant mice. Immunobiology 217: 823-830.
37. Kawamura T, Liu D, Towle MJ, Kageyama R, Tsukahara N, Wakabayashi T, et al. (2003). Anti-angiogenesis effects of borrelidin are mediated through distinct pathways: threonyl-tRNA synthetase and caspases are independently involved in suppression of proliferation and induction of apoptosis in endothelial cells. J Antibiot 56: 709-715.
38. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
39. Kinyanjui SM, Mwangi T, Bull PC, Newbold CI, Marsh K, (2004). Protection against clinical malaria by heterologous immunoglobulin G antibodies against malaria-infected erythrocyte variant surface antigens requires interaction with asymptomatic infections. J Infect Dis 190: 1527-1533.
40. Langhorne J, Ndungu FM, Sponaas AM, Marsh K, (2008). Immunity to malaria: more questions than answers. Nat Immunol 9: 725-732.
41. Linares M, Albizua E, Mendez D, Rubio JM, Martinez-Serna A, Martinez MA, et al. (2011). Malaria hidden in a patient with diffuse large B-cell lymphoma and sickle cell trait. J Clin Microbiol 49: 4401-4404.
42. Long TT, Nakazawa S, Huaman MC, Kanbara H, (2002). Influence of antimalarial treatment on acquisition of immunity in Plasmodium berghei NK65 malaria. Clin Diagn Lab Immun 9: 933-934.
43. Matteelli A, Castelli F, Caligaris S, (1997). Life cycle of malaria parasites. In:, Carosi G, Castelli F, (eds). Handbook of Malaria Infection in the Tropics, 1st edn. Associazione Italiana "Amici di R. Follereau": Bologna, pp. 17-23.
44. Moneriz C, Marin-Garcia P, Bautista JM, Diez A, Puyet A, (2009). Haemoglobin interference and increased sensitivity of fluorimetric assays for quantification of low-parasitaemia Plasmodium infected erythrocytes. Malar J 8: 279.
45. Mota MM, Brown KN, Holder AA, Jarra W, (1998). Acute Plasmodium chabaudi chabaudi malaria infection induces antibodies which bind to the surfaces of parasitized erythrocytes and promote their phagocytosis by macrophages in vitro. Infect Immun 66: 4080-4086.
46. Mota MM, Brown KN, Do Rosario VE, Holder AA, Jarra W, (2001). Antibody recognition of rodent malaria parasite antigens exposed at the infected erythrocyte surface: specificity of immunity generated in hyperimmune mice. Infect Immun 69: 2535-2541.
47. Ocana-Morgner C, Mota MM, Rodriguez A, (2003). Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med 197: 143-151.
48. Otoguro K, Ui H, Ishiyama A, Kobayashi M, Togashi H, Takahashi Y, et al. (2003). In vitro and in vivo antimalarial activities of a non-glycosidic 18-membered macrolide antibiotic, borrelidin, against drug-resistant strains of Plasmodia. J Antibiot (Tokyo) 56: 727-729.
49. Peters W, Robinson B, (1999). Malaria. In:, Zak O, Sande M, (eds). Handbook of Animal Models of Infection, 1st edn. Academic Press: San Diego, CA, pp. 757-773.
50. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N, et al. (2002). Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360: 610-617.
51. Proudfoot O, Drew N, Scholzen A, Xiang S, Plebanski M, (2008). Investigation of a novel approach to scoring Giemsa-stained malaria-infected thin blood films. Malar J 7: 62.
52. Pullen GR, Fitzgerald MG, Hosking CS, (1986). Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 86: 83-87.
53. Radfar A, Mendez D, Moneriz C, Linares M, Marin-Garcia P, Puyet A, et al. (2009). Synchronous culture of Plasmodium falciparum at high parasitemia levels. Nat Protoc 4: 1899-1915.
54. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. (2009). Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361: 468-477.
55. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, et al. (2011). Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377: 1770-1776.
56. Sauerwein RW, Bijker EM, Richie TL, (2010). Empowering malaria vaccination by drug administration. Curr Opin Immunol 22: 367-373.
57. Schimmel P, Tao J, Hill J, (1998). Aminoacyl tRNA synthetases as targets for new anti-infectives. FASEB J 12: 1599-1609.
58. Scholar EC, Pratt WB, (1939). The Antimicrobial Drugs, 2nd edn. Oxford University Press: New York.
59. Stevenson MM, Riley EM, (2004). Innate immunity to malaria. Nat Rev 4: 169-180.
60. Sutherland R, Boon RJ, Griffin KE, Masters PJ, Slocombe B, White AR, (1985). Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother 27: 495-498.
61. Thelu J, Sheick-Zakiuddin I, Boudin C, Peyron F, Picot S, Ambroise-Thomas P, (1991). Development of natural immunity in Plasmodium falciparum malaria: study of antibody response by Western immunoblotting. J Clin Microbiol 29: 510-518.
62. Thomas CM, Hothersall J, Willis CL, Simpson TJ, (2010). Resistance to and synthesis of the antibiotic mupirocin. Nat Rev Microbiol 8: 281-289.
63. Tsuchiya E, Yukawa M, Miyakawa T, Kimura KI, Takahashi H, (2001). Borrelidin inhibits a cyclin-dependent kinase (CDK), Cdc28/Cln2, of Saccharomyces cerevisiae. J Antibiot 54: 84-90.
64. Urban B, Ing R, Stevenson M, (2005). Early interactions between blood-stage plasmodium parasites and the immune system. Curr Top Microbiol Immunol 297: 25-70.
65. Vedi S, Dangi A, Hajela K, Misra-Bhattacharya S, (2008). Vaccination with 73 kDa recombinant heavy chain myosin generates high level of protection against Brugia malayi challenge in jird and mastomys models. Vaccine 26: 5997-6005.
66. Wakabayashi T, Kageyama R, Naruse N, Tsukahara N, Funahashi Y, Kitoh K, et al. (1997). Borrelidin is an angiogenesis inhibitor; disruption of angiogenic capillary vessels in a rat aorta matrix culture model. J Antibiot (Tokyo) 50: 671-676.
67. Weiss GE, Crompton PD, Li S, Walsh LA, Moir S, Traore B, et al. (2009). Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol 183: 2176-2182.
68. Wilson NS, Behrens GM, Lundie RJ, Smith CM, Waithman J, Young L, et al. (2006). Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 7: 165-172.
69. World Health Organization (2010). Guidelines for the Treatment of Malaria. World Health Organization: Geneva.